These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 7985276)

  • 21. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S; Meissner AJ; Filipecki S; Zawilska K; Sowier J; Ciesielski L; Bielawiec M; Glowinski S; Czestochowska E
    Thromb Haemost; 1992 Jul; 68(1):14-8. PubMed ID: 1325076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
    Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
    Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials.
    Howard AW; Aaron SD
    Thromb Haemost; 1998 May; 79(5):902-6. PubMed ID: 9609217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anticoagulant and thrombolytic therapy in deep venous thrombosis and pulmonary embolism].
    Nielsen HK; Lassen JF; Ravn HB; Husted SE
    Ugeskr Laeger; 1995 May; 157(20):2835-40. PubMed ID: 7785097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.
    Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A
    Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
    Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
    Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.
    Noble LS; Kutteh WH; Lashey N; Franklin RD; Herrada J
    Fertil Steril; 2005 Mar; 83(3):684-90. PubMed ID: 15749498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low molecular weight heparin therapy: is monitoring needed?
    Boneu B
    Thromb Haemost; 1994 Sep; 72(3):330-4. PubMed ID: 7855780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Schramm W; Kirchhof B; Bergemann R
    Haemostasis; 1997; 27(2):65-74. PubMed ID: 9212354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis].
    Zhai ZG; Wang C; Liu YM; Qin ZQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):221-6. PubMed ID: 15266820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.